Showing posts with label hope for adhesion pain. Show all posts
Showing posts with label hope for adhesion pain. Show all posts

Monday, March 31, 2014

Poor Pup is also a Victim of adhesions

Lulu Undergoes Five-Hour Surgery at Angell Memorial Hospital

Doctors found more internal problems during Lulu's operation. She is being monitored for the next several days at Angell Memorial Hospital.
Brought to you by findmassmoney.com
Lulu. Photo credit: GoFundMe page.
Lulu. Photo credit: GoFundMe page.
Kimberly Hammond Donahue updated all of Lulu’s fans about how the German Shepherd is doing after Lulu underwent a five-hour surgery at Angell Memorial Hospitalon Monday. 
On the GoFundMe fundraising pagethat Donahue created to raise funds for Lulu’s surgery, Donahue wrote on Monday:
“I am so eternally grateful for everyone that has helped me with this endeavor... I truly am and will be forever... Lulu had almost 5 hours of surgery today... She is being monitored for several days to avoid any complications, but we are not unfortunately out of the woods yet. They found so many more problems internally than originally thought... She had multiple adhesions and scar tissue internally...from who knows what... nor do I want to know. They were able to relieve a band of adhesions that were limiting and constricting her esophagus, resulting in the mega esophagus. They also discovered that one of her lungs was actually adhered to her abdominal cavity... they were able to free it and feel that they did not puncture or compromise her lung. This will be a long road of recovery and depending upon the outcome I may do more fund raising. I believe that all things happen for a reason...she came to all of us, and we have come a long way, and made tremendous strides. Please keep checking back as I want all of the prayers that can be offered... I will post updates as I know more...THANK GOD for Angell Memorial Hospital ....” 
Lulu was abandoned at the Spoiled Rotten Doggy Daycare and Donahue volunteered to take her in. The dog has a medical condition called esophageal diverticulitis, which requires immediate corrective surgery to allow her to eat and not regurgitate her food. The problem hasn’t been treated for years, said Donahue.
If she didn’t get the surgery, her condition would have worsened and could have lead to a secondary condition, such as an infection in her lungs, which can be fatal.
Lulu’s story went international after Donahue started fundraising for the dog's operation last month. Money flowed it from around the world as people opened up their wallets for Lulu.
Donahue has raised nearly $18,000 for the operation and post-operation care for Lulu. Any money raised beyond that will be given to the Northeast Animal Shelter.

Wednesday, March 12, 2014

Adhesion Related Disorder ~ A Harrowing account of an emergency c section

February 15, 2014

Scar tissue from surgeries threatens woman's life

MORGANTOWN, Ind.
"The doctor who completed the surgery later described to Jones what he found.
"He'd never seen anything like it. My anatomy was all screwed up. The scar tissue was so bad that he couldn't get in my uterus," Jones said.
Jaxson wasn't breathing when surgeons removed him from his mothers' womb. He was resuscitated and rushed to neonatal intensive care.
At the same time, Jones had been injured in the fight to get her son out of her body. Two ropes of scar tissue wrapped around her bladder squeezed and tore the organ in two.
A nine-hour surgery was required to keep her alive.
"When the doctor came out, I rushed up and wanted to thank the man who had saved my daughter's life," Holt said. "He said, 'Thanks needs to be given somewhere else. There was a higher power and angels in that room. In any other circumstances, she and Jaxson wouldn't have made it."
Jones survived and has recovered somewhat. But she has reached the point where her adhesions will likely end her life unless the scar tissue is cleaned out.
Doctors have told her using conventional treatment, it would take surgeons days to clean out and remove all of the scar tissue that is causing her problems.
Even if that were a realistic option, the current methods would create more scar tissue. Her adhesions would come back as bad, if not worse, than before.
"Everything is being torn and twisted and strangled. Doctors have told us she's basically a ticking time bomb," Holt said. "Her bladder is being strangled, and her colon is being strangled."
But for the first time in years, Jones has hope. She has found a doctor who has developed a revolutionary method that would remove the adhesions without bringing them back.
Dr. Constantine Frantzides, with the Chicago Institute of Minimally Invasive Surgery, would create a tiny incision under the ribs. Layer by layer, he could take the scar tissue out."
- See more at: http://www.goshennews.com/statenews/x1708326995/Scar-tissue-from-surgeries-threatens-womans-life#sthash.sXOYFtGI.dpuf

Thursday, December 05, 2013

Potential for scar tissue treatment

Posted: Tuesday, November 12, 2013 10:23 am | Updated: 10:31 am, Tue Nov 12, 2013.

Researchers from Scotland have identified a specific molecule responsible for turning regular tissue into scar tissue.
Using mice bred with the disease fibrosis, researchers from the University of Edinburgh developed a drug which blocked a molecule called alpha v integrin. Mice treated with the drug were protected from liver and lung fibrosis. The discovery could help patients with damaged organs avoid the long wait on organ transplant lists.

Thursday, November 17, 2011

Effect of bovine amniotic fluid on intra-abdominal adhesion in diabetic male rats.

J Diabetes Complications. 2011 Jan-Feb;25(1):39-43. Epub 2009 Oct 13.
Effect of bovine amniotic fluid on intra-abdominal adhesion in diabetic male rats.
Abbasian B, Kazemini H, Esmaeili A, Adibi S.
SourceFaculty of Veterinary Medicine, Shahrekord Azad University, Shahrekord, Iran.

Abstract
BACKGROUND: Postsurgical adhesion formation is a significant clinical problem within every surgical specialty. In type I diabetic patients, the problem is more severe and wound healing is slow. A wide variety of treatments have been proposed to deal with the problems that adhesion causes. One of the modalities that have not been studied extensively yet is the use of amniotic fluid. The purpose of the present study was to evaluate the clinical value of bovine amniotic fluid (BAF) efficacy in the treatment of postsurgical adhesion formation in diabetic male rats.

MATERIALS AND METHODS: Fifty male Wistar rats in five groups were used for our study, with animal identification being facilitated by a microchip implant system. Diabetes was induced in all groups except for the control group by intraperitoneal alloxan injection (120 mg/kg). Based upon blood glucose concentration, rats received either one third of the required insulin (two groups) or all the required insulin (remaining groups). After 2 weeks, a laparotomy was performed on each rat and adhesions were scaled. Bovine amniotic fluid was then applied to two groups, and, as a control, sterilized water was applied to the other groups. After 2 weeks, a laparotomy was again performed on each rat and adhesion was rescored.

RESULTS AND CONCLUSION: Significant reductions (P<.05) in adhesions were seen with BAF only in those diabetic rats that had received the required insulin. The results of our study suggest that BAF could be effective in the treatment of adhesion formation during diabetes.

Copyright © 2011 Elsevier Inc. All rights reserved.

PMID:19828333[PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/pubmed/19828333

Agreement With Innocoll for Surgical Adhesion Barrier CollaGUARD

TORONTO, ONTARIO, Nov 14, 2011 (MARKETWIRE via COMTEX) -- Envoy Capital Group Inc. /quotes/zigman/38441 CA:ECG +8.46% /quotes/zigman/38429/quotes/nls/ecgi ECGI +0.94% ("Envoy") announces that Merus Labs International Inc. (cnsx:MR) ("Merus") has entered into a License and Distribution Agreement with Innocoll in Canada for CollaGUARD surgical adhesion barrier for the prevention of postoperative adhesions following abdominal and pelvic surgery. Envoy and Merus Labs have agreed to amalgamate subject to shareholder and regulatory approval as earlier announced. Meetings of shareholder of Envoy and Merus have been scheduled for December 9, 2011.

"Adhesions occur after most surgical procedures, and are of major clinical, social and economic concern. The addition of CollaGUARD to our portfolio means that thousands of patients at risk of adhesion will have a clinically proven superior solution. We look forward to obtaining Health Canada approval and the launch of CollaGUARD in 2012." said Ali Moghaddam, Vice President at Merus Labs.

Dr. Michael Myers, President and CEO of Innocoll stated, "We are pleased to announce the expansion of our partnership with Merus to include CollaGUARD and we look forward to the successful launch of the product in Canada."

About CollaGUARD(R)

CollaGUARD is a transparent bioresorbable film of 100% type I collagen developed using Innocoll's proprietary CollaFilm technology. It is approved in Europe for the prevention of postoperative adhesions in patients undergoing abdominopelvic laparotomy or laparoscopy. When tested in vivo, CollaGUARD increased the probability of remaining adhesion-free by more than six fold (P less than 0.001) and significantly reduced the extent and severity of adhesions (P less than 0.001).

CollaGUARD has been designed and engineered with a unique combination of features for optimal handling, ease-of-use, and antiadhesion performance. It is highly stable at room temperature and does not require any advanced preparation before use. The product is non-tacky and can be easily rolled for insertion through a trocar when implanted laparoscopically. CollaGUARD is available in a wide variety of sizes up to 20 x 30 cm; it may be cut and sutured if required and therefore used efficiently across a broad range of surgeries.

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R), CollaFilm, DermaSil(TM), CollaPress(TM) and Liquicoll(R). Approved products based on the Company's technologies include: Collatamp(R) G, Septocoll(R), CollaGUARD, Collieva(R), CollaCare(R), Collexa(R), Zorpreva(TM), and LidoColl(R).

Other products in clinical and regulatory development include: CollaRx Gentamicin Surgical Implant in phase 3 for prevention of surgical wound infections, Cogenzia in phase 3 for the adjuvant treatment of infected diabetic foot ulcers, and Xaracoll in phase 2b for the management of post-operative pain. For more information, please visit www.innocollinc.com .
Read More : http://www.marketwatch.com/story/envoy-capital-announces-merus-labs-licensing-agreement-with-innocoll-for-surgical-adhesion-barrier-collaguard-2011-11-14-943190?reflink=MW_news_stmp

Wednesday, October 05, 2011

Abdominal Adhesions ~ NATIONAL INSTITUTES OF HEALTH

National Digestive Diseases Information Clearinghouse
U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH
What are abdominal adhesions?
Abdominal adhesions are bands of tissue that form between abdominal tissues and organs. Normally, internal tissues and organs have slippery surfaces, which allow them to shift easily as the body moves. Adhesions cause tissues and organs to stick together.
Although most adhesions cause no symptoms or problems, others cause chronic abdominal or pelvic pain. Adhesions are also a major cause of intestinal obstruction and female infertility.
What causes abdominal adhesions?
Abdominal surgery is the most frequent cause of abdominal adhesions. Almost everyone who undergoes abdominal surgery develops adhesions; however, the risk is greater after operations on the lower abdomen and pelvis, including bowel and gynecological surgeries. Adhesions can become larger and tighter as time passes, causing problems years after surgery.
Surgery-induced causes of abdominal adhesions include

tissue incisions, especially those involving internal organs

the handling of internal organs

the drying out of internal organs and tissues

contact of internal tissues with foreign materials, such as gauze, surgical gloves, and stitches
The intestines are part of the digestive system. Abdominal adhesions can cause an intestinal obstruction.

blood or blood clots that were not rinsed out during surgery
A less common cause of abdominal adhesions is inflammation from sources not related to surgery, including

appendicitis—in particular, appendix rupture

radiation treatment for cancer

gynecological infections

abdominal infections

Rarely, abdominal adhesions form without apparent cause.


How can abdominal adhesions cause intestinal obstruction?
Abdominal adhesions can kink, twist, or pull the intestines out of place, causing an intestinal obstruction. An intestinal obstruction partially or completely restricts the movement of food or stool through the intestines. A complete intestinal obstruction is life threatening and requires immediate medical attention and often surgery.
How can abdominal adhesions cause female infertility?
Abdominal adhesions cause female infertility by preventing fertilized eggs from reaching the uterus, where fetal development takes place. Adhesions can kink, twist, or pull out of place the fallopian tubes, which carry eggs from the ovaries—where eggs are stored and released—to the uterus.
What are the symptoms of abdominal adhesions?
Although most abdominal adhesions go unnoticed, the most common symptom is chronic abdominal or pelvic pain. The pain often mimics that of other conditions, including appendicitis, endometriosis, and diverticulitis.
What are the symptoms of an intestinal obstruction?
Symptoms of an intestinal obstruction include

severe abdominal pain or cramping

vomiting

bloating

loud bowel sounds

swelling of the abdomen

inability to pass gas

constipation
A person with these symptoms should seek medical attention immediately.
How are abdominal adhesions and intestinal obstructions diagnosed?
No tests are available to diagnose adhesions, and adhesions cannot be seen through imaging techniques such as x rays or ultrasound. Most adhesions are found during exploratory surgery. An intestinal obstruction, however, can be seen through abdominal x rays, barium contrast studies—also called a lower GI series—and computerized tomography.
How are abdominal adhesions and intestinal obstructions treated?
Treatment for abdominal adhesions is usually not necessary, as most do not cause problems. Surgery is currently the only way to break adhesions that cause pain, intestinal obstruction, or fertility problems. More surgery, however, carries the risk of additional adhesions and is avoided when possible.
A complete intestinal obstruction usually requires immediate surgery. A partial obstruction can sometimes be relieved with a liquid or low-residue diet. A low-residue diet is high in dairy products, low in fi ber, and more easily broken down into smaller particles by the digestive system.
Can abdominal adhesions be prevented?
Abdominal adhesions are difficult to prevent; however, surgical technique can minimize adhesions.
Laparoscopic surgery avoids opening up the abdomen with a large incision. Instead, the abdomen is inflated with gas while special surgical tools and a video camera are threaded through a few, small abdominal incisions. Inflating the abdomen gives the surgeon room to operate.
If a large abdominal incision is required, a special filmlike material (Seprafi lm) can be inserted between organs or between the organs and the abdominal incision at the end of surgery. The filmlike material, which looks similar to wax paper, is absorbed by the body in about a week.
Other steps during surgery to reduce adhesion formation include using starch- and latex-free gloves, handling tissues and organs gently, shortening surgery time, and not allowing tissues to dry out.
Points to Remember

Abdominal adhesions are bands of tissue that form between abdominal tissues and organs, causing tissues and organs to stick together.

Although most adhesions cause no symptoms or problems, others cause chronic abdominal or pelvic pain, bowel obstruction, or female infertility.

Abdominal surgery is the most frequent cause of abdominal adhesions.

Abdominal adhesions can kink, twist, or pull the intestines out of place, causing an intestinal obstruction.

A complete intestinal obstruction is life threatening and requires immediate medical attention and often surgery.

Abdominal adhesions cause female infertility by preventing fertilized eggs from reaching the uterus, where fetal development takes place.

No tests are available to diagnose adhesions, and adhesions cannot be seen through imaging techniques such as x rays or ultrasound.

An intestinal obstruction can be seen through abdominal x rays, barium contrast studies—also called a lower GI series—and computerized tomography.

Surgery is currently the only way to break adhesions that cause pain, intestinal obstruction, or fertility problems.

Hope through Research
The National Institute of Diabetes and Digestive and Kidney Diseases conducts and supports basic and clinical research into many digestive disorders.
Participants in clinical trials can play a more active role in their own health care, gain access to new research treatments before they are widely available, and help others by contributing to medical research. For information about current studies, visit http://www.clinicaltrials.gov/ .

Abdominal Adhesions
For More Information
American College of Gastroenterology P.O. Box 342260 Bethesda, MD 20827–2260 Phone: 301–263–9000 Fax: 301–263–9025 Email: info@acg.gi.org  Internet: http://www.acg.gi.org/
International Foundation for Functional Gastrointestinal Disorders P.O. Box 170864 Milwaukee, WI 53217–8076 Phone: 1–888–964–2001 or 414–964–1799 Fax: 414–964–7176 Email: iffgd@iffgd.org  Internet: http://www.iffgd.org/
You may also find additional information about this topic by

searching the NIDDK Reference Collection at www.catalog.niddk.nih.gov/resources

visiting MedlinePlus at http://www.medlineplus.gov/
This publication may contain information about medications. When prepared, this publication included the most current information available. For updates or for questions about any medications, contact the U.S. Food and Drug Administration toll-free at 1–888–INFO–FDA (463–6332) or visit http://www.fda.gov/ . Consult your doctor for more information.
The U.S. Government does not endorse or favor any specific commercial product or company. Trade, proprietary, or company names appearing in this document are used only because they are considered necessary in the context of the information provided. If a product is not mentioned, the omission does not mean or imply that the product is unsatisfactory.
National Digestive Diseases Information Clearinghouse
2 Information Way
Bethesda, MD 20892–3570
Phone: 1–800–891–5389
TTY: 1–866–569–1162
Fax: 703–738–4929
Email: nddic@info.niddk.nih.gov
Internet: http://www.digestive.niddk.nih.gov/
The National Digestive Diseases Information Clearinghouse (NDDIC) is a service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK is part of the National Institutes of Health of the U.S. Department of Health and Human Services. Established in 1980, the Clearinghouse provides information about digestive diseases to people with digestive disorders and to their families, health care professionals, and the public. The NDDIC answers inquiries, develops and distributes publications, and works closely with professional and patient organizations and Government agencies to coordinate resources about digestive diseases.
Publications produced by the Clearinghouse are carefully reviewed by both NIDDK scientists and outside experts. This publication was reviewed by James M. Becker, M.D., F.A.C.S., Boston University Medical Center, and Arthur F. Stucchi, Ph.D., and Karen L. Reed, Ph.D., Boston University School of Medicine.
This publication is not copyrighted. The Clearinghouse encourages users of this fact sheet to duplicate and distribute as many copies as desired.
This fact sheet is also available at http://www.digestive.niddk.nih.gov/ .
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health
NIH Publication No. 09–5037 January 2009
http://digestive.niddk.nih.gov/ddiseases/pubs/intestinaladhesions/AbdominalAdhesions.pdf

Tuesday, October 04, 2011

The inpatient burden of abdominal and gynecological adhesiolysis in the US

Vanja Sikirica1 , Bela Bapat2 , Sean D Candrilli2 , Keith L Davis2 , Malcolm Wilson3 and Alan Johns4

1 Shire Pharmaceuticals, Wayne, PA 19087 USA

2 RTI Health Solutions, 200 Park Offices, Research Triangle Park, NC 27709 USA

3 The Christie NHS Foundation Trust, Manchester, M20 4BX, UK

4 Texas Health Care, Fort Worth, TX 76109 USA

author email corresponding author email

BMC Surgery 2011, 11:13doi:10.1186/1471-2482-11-13

The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1471-2482/11/13

Received: 5 January 2011
Accepted: 9 June 2011
Published: 9 June 2011

© 2011 Sikirica et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Abstract
Background
Adhesions are fibrous bands of scar tissue, often a result of surgery, that form between internal organs and tissues, joining them together abnormally. Postoperative adhesions frequently occur following abdominal surgery, and are associated with a large economic burden. This study examines the inpatient burden of adhesiolysis in the United States (i.e., number and rate of events, cost, length of stay [LOS]).

Methods
Hospital discharge data for patients with primary and secondary adhesiolysis were analyzed using the 2005 Healthcare Cost and Utilization Project's Nationwide Inpatient Sample. Procedures were aggregated by body system.

Results
We identified 351,777 adhesiolysis-related hospitalizations: 23.2% for primary and 76.8% for secondary adhesiolysis. The average LOS was 7.8 days for primary adhesiolysis. We found that 967,332 days of care were attributed to adhesiolysis-related procedures, with inpatient expenditures totaling $2.3 billion ($1.4 billion for primary adhesiolysis; $926 million for secondary adhesiolysis). Hospitalizations for adhesiolysis increased steadily by age and were higher for women. Of secondary adhesiolysis procedures, 46.3% involved the female reproductive tract, resulting in 57,005 additional days of care and $220 million in attributable costs.

Conclusions
Adhesiolysis remain an important surgical problem in the United States. Hospitalization for this condition leads to high direct surgical costs, which should be of interest to providers and payers.

Keywords: Adhesions; adhesiolysis; abdominal; gynecological; burden of illness; hospitalizationsBackground
Adhesions are fibrous bands of scar tissue, often result of surgery, that form between internal organs and tissues, joining them together abnormally [1]. Postoperative adhesions frequently occur following abdominal surgery and are a leading cause of intestinal obstruction. It has been estimated that more than 90% of patients who undergo abdominal operations will develop postoperative adhesions [2].

The most severe complication of postoperative adhesions is small bowel obstruction (SBO), which has a 10% risk of mortality [3,4]. Recent research has demonstrated that readmission episodes averaged 2.7 per patient for SBO or nonspecific abdominal pain (when adhesions were considered likely). Inpatient readmissions accounted for 87% of episodes; 47% of those required repeat surgery [5]. Additionally, in the large retrospective study Surgical and Clinical Adhesions Research, surgical procedures performed on the bowel or the female reproductive system were associated with an increased chance of adhesion development, termed adhesiolysis [6-8]. Ray and colleagues found that 47% of adhesiolysis-related inpatient hospitalizations were for procedures involving the female reproductive tract [2]. Postoperative adhesiolysis-related SBO occurred in 2.8% of patients undergoing hysterectomy for benign conditions and in 5% of those undergoing radical hysterectomy [4,9].

A number of studies have shown that the economic burden of adhesiolysis is significant [2,5,10]. It was estimated that adhesiolysis procedures resulted in 303,836 hospitalizations, 846,415 days of inpatient care, and nearly $1.3 billion in health care expenditures in the United States (US) in 1994 [2]. This cost has decreased when compared with similar data from 1988,[10] due in part to laparoscopic surgery. Despite the decrease in costs associated with laparoscopic surgery, increased use of such techniques did not lead to a decreased rate of overall hospitalizations [2].

Utilizing more recent data, we estimated the current burden of inpatient treatment of adhesiolysis in the US. This study examined the number and rate of adhesiolysis-related hospitalizations, days of care attributable to adhesiolysis, and length of stay (LOS) for adhesiolysis-related hospitalizations, with primary and secondary procedures considered separately. Additionally, we assessed total inpatient costs attributable to adhesiolysis.

Methods
Data Source
Data were taken from the 2005 Healthcare Cost and Utilization Project's (HCUP) Nationwide Inpatient Sample (NIS)[11]. The NIS is the largest all-payer inpatient care database in the US and contains data from approximately 8 million hospital stays in 2005. The database also contains clinical and resource use information, including patient demographics, International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis and procedure codes, diagnosis-related group (DRG) codes, LOS, charges, discharge status, payer source, and hospital-specific characteristics. Using the survey design elements provided with the NIS, data can be weighted to produce nationally representative estimates [12]. All financial information in the NIS database is presented as charges rather than costs. To convert hospital charges to costs, facility-specific cost-to-charge ratios were used. Finally, the medical care component of the Consumer Price Index was applied to inflate all financial data to 2007 US dollars [13].

RTI International's Institutional Review Board determined that this study met all criteria for exemption.

Study Sample
From the NIS, all hospitalizations containing a DRG code of peritoneal adhesiolysis with or without complications (i.e., DRG 150, 151) were defined as primary adhesiolysis-related hospitalizations. Hospitalizations containing a primary or nonprimary ICD-9-CM procedure code for adhesiolysis, but without DRG 150 or 151, were defined as secondary adhesiolysis-related hospitalizations (Table 1). Hospitalizations related to secondary adhesiolysis were stratified by body system, using the following DRG coding:

(1) Digestive system (i.e., DRG 148, 149, 154, or 468),

(2) Hepatobiliary system (i.e., DRG 197, 493, or 494),

(3) Female reproductive system (i.e., DRG 358, 359, 361, or 365),

(4) Pregnancy with evidence of Cesarean section (i.e., DRG 370, 371, or 378).

Table 1. Description of Procedure (ICD-9-CM) Codes Used to Identify Adhesiolysis-Related Surgical Procedures

.Study Measures
Study measures included the number of inpatient hospitalizations involving adhesiolysis, adhesiolysis-related hospitalization rates, days of care, and costs attributable to adhesiolysis.

Hospitalization rates per 100,000 persons were assessed using the US Census Bureau's 2005 total US civilian population projection. The total days of care attributable to adhesiolysis were estimated using methods presented by Ray and colleagues that then were adapted for the HCUP NIS [2]. When DRG 150 or 151 (i.e., primary adhesiolysis) was the primary reason for admission, the attributed LOS was simply the mean LOS for this group. For records without a DRG of 150 or 151, excess days attributed to adhesiolysis were calculated as the difference between the mean LOS for those same procedures with adhesiolysis and those procedures without adhesiolysis within each DRG. The total number of adhesiolysis-related days then was estimated as the product of the attributed LOS for the group and the number of adhesiolysis-related hospitalizations within the group.

This study utilized the methodology from Ray and colleagues to estimate the per-day cost attributable to adhesiolysis [2]. Cost per day was estimated by dividing the total cost of adhesiolysis-related hospitalizations divided by the total number of adhesiolysis-related inpatient days. The total inpatient expenditures attributable to adhesiolysis were estimated by multiplying the estimated cost per day attributable to adhesiolysis by the number of days attributed to adhesiolysis.

Average expenditures for surgeon's services were estimated using the Resource-Based Relative Value Scale (RBRVS). The RBRVS value was estimated for Current Procedural Terminology codes related to adhesiolysis (Table 2) and then multiplied by a fixed conversion factor to determine the average surgeon expenditures for each specific procedure. These figures then were inflated to 2007 dollars using the medical care component of the Consumer Price Index.

Table 2. Description of Procedure (CPT) Codes Used to Identify Adhesiolysis-Related Surgical Procedures to Estimate Expenditures for Surgeons' Servicesa

.Total inpatient costs attributable to adhesiolysis consisted of inpatient costs and costs for the surgeon's services. Estimates were made separately for primary and secondary adhesiolysis. These also were examined by body system and then aggregated to estimate a total cost. Additionally, inpatient expenditures were summarized to compare Cesarean section deliveries with and without adhesiolysis.

Statistical Analyses
Descriptive analyses were conducted to display the mean, standard deviation, median, and range of continuous variables, as well as the frequency distribution of categorical variables. All data management and analyses were conducted with SAS and SUDAAN statistical software packages [14,15].

Results and Discussion
Table 3 illustrates that there were 351,777 adhesiolysis-related hospitalizations in the US in 2005, representing 119 adhesiolysis hospitalizations per 100,000 persons. There were 898 adhesiolysis hospitalizations per 100,000 hospitalizations and 3,549 per 100,000 surgical hospitalizations of any kind (3.5%). Primary adhesiolysis (i.e., DRG 150 or 151) was found in 23.2% of these hospitalizations, while the remaining 76.8% were classified as secondary adhesiolysis (i.e., evidence of the procedure but with a DRG other than 150 or 151).

Table 3. Rate of Adhesiolysis-Related Hospitalizations

.Table 4 presents background characteristics for the study sample. For primary adhesiolysis, the number of hospitalizations increased steadily by age; for secondary adhesiolysis, the number increased for most age categories. The lowest rate was in patients who were younger than 25 years (5.2 per 100,000 persons for primary adhesiolysis; 13.8 per 100,000 persons for secondary adhesiolysis), and the highest rate was in patients who were older than 65 years (88.4 per 100,000 persons for primary adhesiolysis; 176.7 per 100,000 persons for secondary adhesiolysis). Women had a higher hospitalization rate than men (34.9 vs. 19.7 per 100,000 persons for primary adhesiolysis; 153.1 vs. 13.4 per 100,000 persons for secondary adhesiolysis). Among primary adhesiolysis hospitalizations, almost half (48%) of the patients were admitted via the emergency department, whereas only 20.5% of the secondary adhesiolysis hospitalizations were via the emergency department. Primary adhesiolysis-related hospitalizations were evenly distributed between private insurance and governmental coverage, i.e., Medicaid and Medicare (44% and 48%, respectively), whereas more than half (56%) of the patients with secondary adhesiolysis hospitalizations had private insurance and 37.4% had government-sponsored health care coverage.

Table 4. Demographics and Other Patient- and Facility-Specific Characteristics of Interest Among Adhesiolysis-Related Hospitalizations (i.e., DRG 150 or 151) in the US in 2005

.A total of 967,332 inpatient days of care were attributed to primary and secondary adhesiolysis (Table 5). There were 81,532 hospitalizations and an average LOS of 7.8 days per stay, totaling 632,688 inpatient days of care for primary adhesiolysis. An estimated 334,644 days of care were attributed to secondary adhesiolysis. For hospitalizations in which adhesiolysis was a secondary procedure, we compared the LOS between adhesiolysis and nonadhesiolysis procedures to estimate the LOS attributable to adhesiolysis by each DRG. The majority of DRGs showed an increase in LOS for adhesiolysis hospitalizations versus nonadhesiolysis hospitalizations. On average, hospitalizations related to secondary adhesiolysis resulted in an additional 1.24 hospitalized days compared with nonadhesiolysis-related hospitalizations.

Table 5. Inpatient Care Attributable to Abdominal Adhesiolysis by Surgical Procedure in the US in 2005

.The difference in mean LOS was greatest for extensive operation room procedures unrelated to principal diagnosis (i.e., DRG 468), with 4.9 days attributable to adhesiolysis. For stomach, esophageal, and duodenal procedures with complications of comorbid conditions (i.e., DRG 154), 4.6 days were attributable to adhesiolysis. Almost half (46.3%) of all secondary adhesiolysis procedures (125,069) were female reproductive tract related, resulting in 57,005 days of care. Thus, 0.46 day of additional stay were attributable to adhesiolysis. The longest LOS for female reproductive system procedures was for DRG 358 (uterine and adnexa procedures for nonmalignancy), which resulted in an additional day of inpatient stay (0.90 day).

Table 6 shows that total inpatient expenditures for adhesiolysis-related hospitalizations were $2.25 billion: of this amount, primary adhesiolysis-related hospitalizations accounted for $1.35 billion and secondary adhesiolysis-related hospitalizations accounted for $902 million. Of the total secondary adhesiolysis expenditures, $622 million (69%) were related to procedures for the digestive system and $220 million (24.3%) were related to procedures for the female reproductive system. Adhesiolysis related to the hepatobiliary system and pancreas and Cesarean sections accounted for $41 million and $18 million, respectively.

Table 6. Inpatient Expenditures Attributable to Abdominal Adhesiolysis in the US in 2005

.The rate of adhesiolysis-related hospitalizations in the US has remained fairly constant from 1998 to 2005: from 115.5 in 1988 [10] to 117.3 in 1994 [2] and ultimately 118.6 per 100,000 persons in 2005. In these same time periods, the average LOS for primary adhesiolysis-related hospitalizations has steadily decreased from 11.2 days to 9.7 days and 7.8 days, respectively. The costs for such hospitalizations, when inflated to reflect 2007 dollars, indicated an increase of $112 million between 1988 and 2005, despite the 3.4-day (or 30%) decrease in LOS--this represented a 5% increase in medical care costs. This increase suggested that costs of treating adhesiolysis have increased substantially.

Primary adhesiolysis contributed 23% of all adhesiolysis procedures (81,532) but represented more than half of the total cost burden ($1.3 billion). Secondary adhesiolysis was substantially higher in volume, representing 77% of procedures (270,245) but less half of the total cost burden ($902 million). The greatest number of procedures was to the female reproductive tract (125,069) while procedures to the digestive tract yielded the highest overall costs ($622 million).

Potentially mitigating this growth in the cost of adhesiolysis may be the continuing trend in the US toward minimally invasive and laparoscopic approaches, which may lessen the occurrence of postoperative adhesions [2]. Although laparoscopy reduces surgical trauma, the procedure has not been show to reduce the incidence of adhesion-related readmissions [16].

This study is subject to potential limitations consistent with retrospective database studies. Conditions and events of interest were identified by diagnosis codes. Previous research has suggested that the condition may be underreported [17]. This may mean that the actual cost of adhesiolysis-related disease is greater than the estimate provided by our study. The database used for this study was not specifically designed to assess inpatient burden. Like all administrative billing databases, the data contained in the HCUP NIS are dependent upon the quality of coding, which may be influenced by reimbursement incentives. However, we do not feel it likely that such incentives greatly affected our results since the majority of overall adhesiolysis costs were a part of secondary adhesiolysis procedures and not the more costly primary adhesiolysis. Moreover, even if such incentives exist and are reflected in the data used for this study, these data are indicative of real world practice. Additionally, with such a large sample, the effect of any coding errors or anomalies would likely be minimized.

Furthermore, due to the nature of the database, detailed clinical characteristics could not be ascertained; therefore, the results could not be adjusted for disease severity or other clinical parameters. However, it is unlikely that these factors would have had a large impact on the results, as this study focused on those patients receiving inpatient care. Additionally, since the database contains US data only, the results may not be generalizable to other populations outside of the US. Lastly, because the focus of this study was on direct cost measures, the results do not account for productivity loss for the patient or caregiver and potential future societal contributions that may be lost due to death resulting from or related to adhesiolysis. Because we examined only the direct health care costs associated with inpatient adhesiolysis, we have not examined any adhesiolysis-related surgeries performed at other sites of care, such as ambulatory surgical centers. Further, our study does not capture direct costs relating to but occurring before or after surgery, including pain medications, cost of work-up visits, and procedures related to diagnosis. Similarly, patient work-ups and diagnostic laparoscopic procedures that may have occurred at separate visits and prior to the adhesiolysis surgery were not captured if specific DRG codes were not listed for those hospitalizations [6,7,9]. Hence, this study's estimates of costs are likely to be conservative.

Conclusions
Adhesions remain an important surgical problem, and hospitalization for adhesiolysis leads to a high direct cost burden in the US. Despite a trend of decreasing LOS for adhesiolysis-related hospitalizations from 2001 to 2005, adhesiolysis-related costs continue to rise even while the overall rate of adhesiolysis procedures remains constant. Consistent with previous research, the distribution of inpatient care and costs across the diagnostic categories remained steady from 2001 to 2005, with only a slight increase in primary adhesiolysis procedures over time. From 2001 to 2005, hospitalizations for adhesiolysis related to the digestive system and to the female reproductive tract had the largest number of inpatient days and accounted for the majority of costs related to secondary adhesiolysis procedures.

Adhesiolysis remains a substantial economic burden to the US health care system, which should be of interest to providers and commercial and government payers. Further research incorporating detailed clinical data and indirect costs would aid in a greater understanding of the overall burden of adhesiolysis.

Competing interests
VS was an employee of Ethicon, Inc. at the time that this manuscript was prepared; he is currently an employee of Shire Pharmaceuticals. BB, SDC, and KLD are employees of RTI Health Solutions, the research organization contracted by Ethicon to conduct this study. AJ is an employee of Texas Healthcare; MW is an employee of Christie NHS Foundation Trust.

Authors' contributions
VS was responsible for developing the study design, interpreting the analysis results, and drafting the manuscript text; he is the primary author of this manuscript. BB, SDC, and KLD were responsible for the acquisition, management, interpretation, and analysis of all study data. BB, SDC, and KLD also assisted with developing the study design, interpreting the analysis results, and drafting the manuscript. AJ and MW contributed clinical expertise and guidance and assisted in interpreting the analysis results and drafting the manuscript text.

All authors confirm that they have read the journal's position on issues involved in ethical publication and affirm that this research report is consistent with those guidelines. Finally, all authors have read and approved the final manuscript.

Funding
This study and the preparation of this manuscript were funded by Ethicon, Inc. The authors acknowledge that Ethicon, Inc. is the maker of GYNECARE INTERCEED, a product that is marketed to prevent pelvic adhesions.

Acknowledgements
Portions of the study data presented in this paper were previously presented as a podium presentation at the VIIIth PAX Meeting; Clermont-Ferrand, France; September 18-20, 2008, as well as a poster presentation at the 57th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists; Chicago, Illinois; May 2-6, 2009.

The authors wish to thank Ms. Gail Zona of RTI Health Solutions and Ms. Heidi Waters of Ethicon, Inc., for assistance with preparing this manuscript.

References
1.Beck DE: Understanding abdominal adhesions.

Ostomy Q 2001, 38(2):50-51.

Return to text


2.Ray NF, Denton WG, Thamer M, Henderson SC, Perry S: Abdominal adhesiolysis: inpatient care and expenditures in the United States in 1994.

J Am Coll Surg 1998, 186(1):1-9. PubMed Abstract | Publisher Full Text

Return to text


3.Menzies D, Parker M, Hoare R, Knight A: Small bowel obstruction due to postoperative adhesions: treatment patterns and associated costs in 110 hospital admissions.

Ann R Coll Surg Engl 2001, 83:40-46. PubMed Abstract | PubMed Central Full Text

Return to text


4.diZerega GS, Tulandi T: Prevention of intra-abdominal adhesions in gynaecological surgery.

Reprod Biomed Online 2008, 17:303-306. PubMed Abstract | Publisher Full Text

Return to text


5.Tingstedt B, Isaksson J, Andersson R: Long-term follow-up and costs analysis following surgery for small bowel obstruction caused by intra-abdominal adhesions.

Br J Surg 2007, 94:743-748. PubMed Abstract | Publisher Full Text

Return to text


6.Ellis H, Moran BJ, Thompson JN, Parker MC, Wilson MS, Menzies D, McGuire A, Lower AM, Hawthorn RJ, O'Brien F, Buchan S, Crowe AM: Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study.

Lancet 1999, 353:1476-1480. PubMed Abstract | Publisher Full Text

Return to text


7.Parker MC, Ellis H, Moran BJ, Thompson JN, Wilson MS, Menzies D, McGuire A, Lower AM, Hawthorn RJ, O'Briena F, Buchan S, Crowe AM: Postoperative adhesions: ten-year follow-up of 12,584 patients undergoing lower abdominal surgery.

Dis Colon Rectum 2001, 44:822-829. PubMed Abstract | Publisher Full Text

Return to text


8.Lower AM, Hawthorn RJ, Ellis H, O'Brien F, Buchan S, Crowe AM: The impact of adhesions on hospital readmissions over ten years after 8489 open gynaecological operations: an assessment from the Surgical and Clinical Adhesions Research Study.

Br J Obstet Gynaecol 2000, 107:855-862. Publisher Full Text

Return to text


9.Meagher AP, Moller C, Hoffmann DC: Non-operative treatment of small bowel obstruction following appendectomy or operation on the ovary or tube.

Br J Surg 1993, 80:1310-1311. PubMed Abstract | Publisher Full Text

Return to text


10.Ray NF, Larsen JW, Stillman RJ, Jacobs RJ: Economic impact of hospitalizations for lower abdominal adhesiolysis in the United States in 1988.

Surg Gynecol Obstet 1993, 176:271-276. PubMed Abstract

Return to text


11.HCUP Nationwide Inpatient Sample. Healthcare Cost and Utilization Project (HCUP) [http://www.hcup-us.ahrq.gov/nisoverview.jsp ] webcite


Return to text


12.Steiner C, Elixhauser A, Schnaier J: The Healthcare Cost and Utilization Project: an overview.

Eff Clin Pract 2002, 5(3):143-151. PubMed Abstract | Publisher Full Text

Return to text


13.US Bureau of Labor Statistics. Consumer Price Index for medical services [http://data.bls.gov/PDQ/outside.jsp?survey=cu] webcite


Return to text


14.SAS Institute Inc: SAS 9.1.3. Cary, NC: SAS Institute Inc; 2003.

Return to text


15.Research Triangle Institute: SUDAAN (Release 9.0.1). Research Triangle Park, NC: Research Triangle Institute; 2005.

Return to text


16.Gutt CN, Oniu T, Schemmer P, Mehrabi A, BĂĽchler MW: Fewer adhesions induced by laparoscopic surgery?

Surg Endosc 2004, 18(6):898-906. PubMed Abstract | Publisher Full Text

Return to text


17.Parker MC, Wilson MS, Menzies D, Sunderland G, Clark DN, Knight AD, Crowe AM, Surgical and Clinical Adhesions Research (SCAR) Group: The SCAR-3 study: 5-year adhesion-related readmission risk following lower abdominal surgical procedures.

Colorectal Dis 2005, 7:551-558. PubMed Abstract | Publisher Full Text

Return to text


Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2482/11/13/prepub

http://www.biomedcentral.com/1471-2482/11/13

Saturday, September 24, 2011

What is adhesions related disorder (ARD)?

Blogger note...this is one of many definitions

Adhesion related disorder is a complex of symptoms related to adhesions. Patient’s primary complaint is usually chronic abdominal pain. Their symptoms can be primarily in one area of the abdomen but are often generalized, vague, crampy and difficult to define. The symptoms of ARD could include:




Chronic pain

Infertility

Bowel obstruction

Gastro-esophageal reflux disease, (GERD)

Urinary Bladder dysfunction

Pain and difficulty having a bowel movement

Pain on movement such as: Walking, sitting or laying in certain positions.

Loss of Nutrients due to poor eating habits or loss of appetite.

Loss of employment due to lost work days

Loss of family and social life

Emotional Disorders such as: Depression, Thoughts of Suicide, Hopelessness

Other intestinal problems can accompany the pain. Constipation or obstruction is sometimes encountered. Alternating constipation with diarrhea from partial obstruction can also be seen. Symptoms may also be related to the gynecologic orders in women as this disorder frequently affects women. Changes in the menstrual cycle, infertility, and pain with sexual intercourse can be encountered. Other symptoms, not directly related to the adhesions, can also be encountered. Since ARD generally results in chronic problems, anxiety and depression can result. Strained relationships can occur especially when the disorder affects sexual function. Difficulty with conception can result. This further adds to the anxiety and problems with self esteem experienced by women who suffer with this disorder. Difficulty eating can result in poor nutrition, weakening suffers overall medical condition and can also lead to a decrease in immune function leading to many other illnesses. Since many of the symptoms related to ARD are vague and wide spread and often include emotional factors, they are often difficult to diagnose. Symptoms of ARD will often be attributed to other abnormalities. Patient will often carry multiple diagnoses including chronic fatigue syndrome, endometriosis, irritable bowel syndrome, fibromyalgia, depression, anxiety, along with a whole host of other possible syndromes. While multiple disorders can certainly exist in one patient, the confusion over which abnormality is truly causing the symptoms adds to the frustration of ARD. This, unfortunately, adds to the discomfort experienced by those who suffer with adhesions. Undiagnosed chronic pain causes so much physical and emotional pain for victims of adhesion related disorder – and fills their lives with so much indecision. In time the effects of ARD will begin to affect the lives of their families, their relationships and their jobs. This inordinate control by ARD has the power to erode and change our lives – and not necessarily for the better! It is so important to believe in yourself, trust the feelings you have about your pain, and tell it like it is. You have the right to be listened to and treated with respect – nothing less!!

Wednesday, September 21, 2011

Karen trying to corner the market on ARD

It appears that Karen Steward will do anything to sell her "ARD Product" line to make a buck off the pain and suffering of those who are already used and abused far to often! Karen speaks out of two sides of her mouth when it comes to ARD. One side she gets your sympathy as one who has suffered the worst of ARD, and out of the other side, Karen is hawking, "BUY MY STUFF" and "LOOK AT ME!"

Who does this sound like..."Kruschinski" of course!

So here you will find Karen sending complaint after complaint to other ARD and Endo wed site hosts, and Google as well as any one else will listen to her and then she forces them to spend time and money with her petty little claims in her attempts to corner the market on the Internet! If she were to succeed in her attempt to gain favorable spots in the search engines by knocking a few other ARD web sites off, she will be able to harvest vulnerable, and desperately ill people to her web sites to buy her merchandise; and ultimately to get them to secure surgery with the "Con Doc, Kruschinski," who rise to notoriety comes from "Profiting from Pain!"

BEWARE of any web site associated with Karen Steward of Wetherford, Texas!



Search Results:
Any contains ELM publishing:
3 matching Notices found; showing 50

Articles DMCA (Copyright) Complaint to Google Karen Steward Google, Inc. [Blogger] July 30, 2011 DMCA Notices
Text DMCA (Copyright) Complaint to Google Karen Steward Google, Inc. [Blogger] July 17, 2011 DMCA Notices
Article DMCA (Copyright) Complaint to Google ELM Publishing, Inc. Google, Inc. [Blogger] May 13, 2011 DMCA Notices

Notice UnavailableDMCA (Copyright) Complaint to Google
Sent by: ELM Publishing, IncTo: Google
The cease-and-desist or legal threat you requested is not yet available.
Chilling Effects will post the notice after we process it.

Question: Why does a web host, blogging service provider, or search engine get DMCA takedown notices?
Answer: Many copyright claimants are making complaints under the Digital Millennium Copyright Act, Section 512(c)'s safe-harbor for hosts of "Information Residing on Systems or Networks At Direction of Users" or Section 512(d)'s safe-harbor for providers of "Information Location Tools." These safe harbors give providers immunity from liability for users' possible copyright infringement -- if they "expeditiously" remove material when they get complaints. Whether or not the provider would have been liable for infringement by users' materials it hosts or links to, the provider can avoid the possibility of a lawsuit for money damages by following the DMCA's takedown procedure when it gets a complaint. The person whose information was removed can file a counter-notification if he or she believes the complaint was erroneous.

Question: What does a service provider have to do in order to qualify for safe harbor protection?
Answer: In addition to informing its customers of its policies, a service provider must follow the proper notice and takedown procedures and also meet several other requirements in order to qualify for exemption under the safe harbor provisions.
In order to facilitate the notification process in cases of infringement, ISPs which allow users to store information on their networks, such as a web hosting service, must designate an agent that will receive the notices from copyright owners that its network contains material which infringes their intellectual property rights. The service provider must then notify the Copyright Office of the agent's name and address and make that information publicly available on its web site. [512(c)(2)]
Finally, the service provider must not have knowledge that the material or activity is infringing or of the fact that the infringing material exists on its network. If it does discover such material before being contacted by the copyright owners, it is instructed to remove, or disable access to, the material itself. The service provider must not gain any financial benefit that is attributable to the infringing material.

Question: What are the provisions of 17 U.S.C. Section 512(c)(3) & 512(d)(3)?
Answer: Section 512(c)(3) sets out the elements for notification under the DMCA. Subsection A (17 U.S.C. 512(c)(3)(A)) states that to be effective a notification must include: 1) a physical/electronic signature of a person authorized to act on behalf of the owner of the infringed right; 2) identification of the copyrighted works claimed to have been infringed; 3) identification of the material that is claimed to be infringing or to be the subject of infringing activity and that is to be removed; 4) information reasonably sufficient to permit the service provider to contact the complaining party (e.g., the address, telephone number, or email address); 5) a statement that the complaining party has a good faith belief that use of the material is not authorized by the copyright owner; and 6) a statement that information in the complaint is accurate and that the complaining party is authorized to act on behalf of the copyright owner. Subsection B (17 U.S.C. 512(c)(3)(B)) states that if the complaining party does not substantially comply with these requirements the notice will not serve as actual notice for the purpose of Section 512.
Section 512(d)(3), which applies to "information location tools" such as search engines and directories, incorporates the above requirements; however, instead of the identification of the allegedly infringing material, the notification must identify the reference or link to the material claimed to be infringing.

Question: Does a service provider have to follow the safe harbor procedures?
Answer: No. An ISP may choose not to follow the DMCA takedown process, and do without the safe harbor. If it would not be liable under pre-DMCA copyright law (for example, because it is not contributorily or vicariously liable, or because there is no underlying copyright infringement), it can still raise those same defenses if it is sued.

Question: How do I file a DMCA counter-notice?
Answer: If you believe your material was removed because of mistake or misidentification, you can file a "counter notification" asking the service provider to put it back up. Chilling Effects offers a form to build your own counter-notice.

For more information on the DMCA Safe Harbors, see the FAQs on DMCA Safe Harbor Provisions. For more information on Copyright and defenses to copyright infringement, see Copyright.

Cease and Desist? What is this site?
The Chilling Effects Clearinghouse collects and analyzes legal complaints about online activity, helping Internet users to know their rights and understand the law. Chilling Effects welcomes submission of letters from individuals and from Internet service providers and hosts. These submissions enable us to study the prevalence of legal threats and allow Internet users to see the source of content removals.
Chilling Effects aims to support lawful online activity against the chill of unwarranted legal threats. We are excited about the new opportunities the Internet offers individuals to express their views, parody politicians, celebrate favorite stars, or criticize businesses, but concerned that not everyone feels the same way. Study to date suggests that cease and desist letters often silence Internet users, whether or not their claims have legal merit. The Chilling Effects project seeks to document that "chill" and inform C&D recipients of their legal rights in response.
The Chilling Effects clearinghouse is a database of cease and desist notices (C&Ds) sent to Internet users, legal interpretation of those notices, Frequently Asked Questions about parts of the law that affect online activity, and related news and resources. If you have received a cease and desist, we invite you to add it to our database.
You can use this site in many different ways: choose a topic area and explore its homepage and FAQs; search the database for C&Ds similar to one you've received or sent; submit your own notice for law students at the participating clinics to analyze.
The site's centerpiece is the database of annotated cease-and-desist notices:
Clinical law students review the notices submitted and link their legalese to explanatory FAQs. As the number of notices grows, so will the selection of FAQs, which can be read either alongside the notices or on their own.

Site Organization
The Chilling Effects clearinghouse is organized by topic area. Some topics are related to types of activity, such as fan fiction and reverse engineering, others to areas of law, such as copyright and trademark. Within each topic, you will find the linked notices, FAQs, related news, and resources such as statutes and articles.
We invite you to report your own notice to the database (received or sent), search or browse the database, or read "Weather Reports" on the legal climate for Internet activity -- compiled based on the notices submitted.

Search
The Chilling Effects clearinghouse offers two types of searches:
Quick Search, the box in the left corner of each index page, searches for words or "quoted phrases" among topics, FAQs, news, resources, and the subject lines of C&D notices.
Search the Database, linked from the header bar, offers a more detailed search of our database of cease-and-desist notices.

Maintained by Chilling Effects
http://www.chillingeffects.org/about

Karen Steward and her "Business Prospects" on Facebook

Many Facebook Users Willingly Give Out Personal Information

December 8th, 2009
Facebook, Internet Safety, Online Reputation Management, Privacy, Social Networking
Rob Frappier

Karen's quote:

#1 karen on 12.11.09 at 8:39 am

Facebook was presented to me as a way to build my business via networking. Many whom I’ve befriended are also on facebook to build their business connections. With that concept, one would have to add unknown friends. Also, if someone simply googles your name, it is easy to find their address, etc. There’s lots of personal information on the internet about a person that the person did not place there themselves. So, please explain how building a network of friends on facebook is any worse than just being alive and vulnerable to GOOGLE.


http://www.reputation.com/blog/2009/12/08/many-facebook-users-willingly-give-out-personal-information/

Saturday, September 17, 2011

Gastroparesis




Gastroparesis diabeticorum; Delayed gastric emptying

Last reviewed: November 11, 2010.



Gastroparesis is a condition that reduces the ability of the stomach to empty its contents, but there is no blockage (obstruction).



Causes, incidence, and risk factors

The cause of gastroparesis is unknown, but it may be caused by a disruption of nerve signals to the stomach. The condition is a common complication of diabetes and can be a complication of some surgeries.



Risk factors for gastroparesis include:



•Diabetes



•Gastrectomy (surgery to remove part of the stomach)



•Systemic sclerosis



•Use of medication that blocks certain nerve signals (anticholinergic medication)



Symptoms

•Abdominal distention



•Hypoglycemia (in people with diabetes)



•Nausea



•Premature abdominal fullness after meals



•Weight loss without trying



•Vomiting



Signs and tests

•Esophagogastroduodenoscopy (EGD)



•Gastric emptying study (using isotope labeling)



•Upper GI series



Treatment

People with diabetes should always control their blood sugar levels. Better control of blood sugar levels may improve symptoms of gastroparesis. Eating small meals and soft (well-cooked) foods may also help relieve some symptoms.



Medications that may help include:



•Cholinergic drugs, which act on acetylcholine nerve receptors



•Erythromycin



•Metoclopramide, a medicine that helps empty the stomach



•Serotonin antagonist drugs, which act on serotonin receptors



Other treatments may include:



•Botulinum toxin (Botox) injected into the outlet of the stomach (pylorus)



•Surgical procedure that creates an opening between the stomach and small intestine to allow food to move through the digestive tract more easily (gastroenterostomy)



Expectations (prognosis)

Many treatments seem to provide only temporary benefit.



Complications

Persistent nausea and vomiting may cause:



•Dehydration



•Electrolyte imbalances



•Malnutrition



People with diabetes may have serious complications from poor blood sugar control.



Calling your health care provider

Apply home treatment such as managing your diet. Call your health care provider if symptoms continue or if you have new symptoms.



References

1.Koch KL. Gastric neuromuscular function and neuromuscular disorders. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 9th ed. Philadelphia, Pa: Saunders Elsevier;2010:chap 48.

Review Date: 11/11/2010.



Reviewed by: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and George F. Longstreth, MD, Department of Gastroenterology, Kaiser Permanente Medical Care Program, San Diego, California. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.

http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001342/

Thursday, September 08, 2011

Adhesion Awareness Giveaway Offers Over $9,700 in Prizes

By on Aug 30, 2011
Virtually all people have adhesions (internal scars). If you scrape your knee, have a fall, undergo surgery or develop an infection, adhesions form to surround the injured area. As the body heals, adhesions often remain at the site of the trauma, surgery, infection or inflammation.


Unfortunately, they can spread to nearby organs, muscles, or nerves, causing unexplained pain or dysfunction. Small but powerful adhesions can act like nylon ropes or straight-jackets, and can cause a myriad of health problems.


Adhesions are often an underlying cause of chronic pain, female infertility, endometriosis pain, and bowel obstructions. Because they are invisible on most diagnostic tests, such as x-rays, CT and MRI scans, they often go undiagnosed by physicians and health care professionals.


Clear Passage Physical Therapy has developed and researched non-invasive treatments for adhesions for over twenty years. Their non-surgical, hands-on therapy (Wurn Technique) uses techniques that feel like a deep massage, to release adhesions that bind structures within the body. In published studies, most patients reported significant pain relief, and a return of function.


In honor of Adhesion Related Disorder (ARD) Awareness Month this September, Clear Passage will donate over $9,700 in treatment and lodging, to three prize winners. Patients who suffer from an ARD can enter this giveaway on the Clear Passage website or on their Facebook page.


The grand prize winner will receive 20 hours of free treatment at Clear Passage’s national headquarters in Gainesville, FL and five days of lodging at a lovely Florida waterfront cottage (a $6,100 value). The second prize winner will receive 10 hours of free treatment (a $2,600 value), and the third prize winner will receive 20 percent off a 20 hour treatment program (a $1,040 value).


“Diagnosing adhesions can be confusing, because they often cross body systems,” says Clear Passage National Director Belinda Wurn, PT. “Many people go from specialist to specialist, sometimes for years, simply searching for a diagnosis. Their problems increase when they learn that the surgery to remove adhesions can often create more adhesions.”


“We are pleased to offer a non-surgical alternative to patients” she said. “It’s very gratifying to give adhesion sufferers back their lives.”


About Clear Passage Physical Therapy

Clear Passage Physical Therapy is a network of high quality physical therapy clinics specializing in hands-on treatment of adhesions, chronic pain, infertility, endometriosis, and bowel obstruction.
http://eyugoslavia.com/featured/30/adhesion-awareness-giveaway-offers-over-9700-in-prizes-2223748/

Saturday, August 20, 2011

ARD Validation Be your own best doctor!

Offering Hope and Help to the Victims of ARD Worldwide



Be your own best doctor!

ARD Validation
for
"Social Security" & "Medical Appoints"
OUR voice DOES make a difference in getting ARD recognized!!!!
THIS report is a MUST to take to your "Medical Appoints"
and to add to your file for applying for "Social Security"
as it validate that "ADHESIONS"
are recognized at the natinal level as the
eitiology (cause) of chronic adominal/pelvic pain!


BIG NEWS!!!
National Institute of Health

World J Surg.2006 Mar 13;
Laparoscopic Lysis of Adhesions.
Szomstein S, Menzo EL, Simpfendorfer C, Zundel N, Rosenthal RJ.
Bariatric Institute, Section of Minimally Invasive Surgery, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd., Weston, Florida, 33331, USA, szomsts@ccf.org.
BACKGROUND: Intra-abdominal adhesions constitute between 49% and 74% of the causes of small bowel obstruction. Traditionally, laparotomy and open adhesiolysis have been the treatment for patients who have failed conservative measures or when clinical and physiologic derangements suggest toxemia and/or ischemia. With the increased popularity of laparoscopy, recent promising reports indicate the feasibility and potential superiority of the minimally invasive approach to the adhesion-encased abdomen. METHODS: The purpose of this study was to assess the outcome of laparoscopic adhesiolysis and to provide technical tips that help in the success of this technique. RESULTS: The most important predictive factor of adhesion formation is a history of previous abdominal surgery ranging from 67%-93% in the literature. Conversely, 31% of scars from previous surgery have been free of adhesions, whereas up to 10% of patients without any prior surgical scars will have spontaneous adhesions of the bowel or omentum. Most intestinal obstructions follow open lower abdominopelvic surgeries such as colectomy, appendectomy, and hysterectomy. The most common complications associated with adhesions are small bowel obstruction (SBO) and chronic pain syndrome. The treatment of uncomplicated SBO is generally conservative, especially with incomplete obstruction and the absence of systemic toxemia, ischemia, or strangulation. When conservative treatment fails, surgical options include conventional open or minimally invasive approaches; the latter have become increasing more popular for lysis of adhesions and the treatment of SBO. Generally, 63% of the length of a laparotomy incision is involved in adhesion formation to the abdominal wall. Furthermore, the incidence of ventral hernia after a laparotomy ranges between 11% and 20% versus the 0.02%-2.4% incidence of port site herniation. Additional benefits of the minimally invasive approaches include a decreased incidence of wound infection and postoperative pneumonia and a more rapid return of bowel function resulting in a shorter hospital stay. In long-term follow up, the success rate of laparoscopic lysis of adhesions remains between 46% and 87%. Operative times for laparoscopy range from 58 to 108 minutes; conversion rates range from 6.7% to 43%; and the incidence of intraoperative enterotomy ranges from 3% to 17.6%. The length of hospitalization is 4-6 days in most series. CONCLUSIONS: Laparoscopic lysis of adhesions seems to be safe in the hands of well-trained laparoscopic surgeons. This technique should be mastered by the advanced laparoscopic surgeon not only for its usefulness in the pathologies discussed here but also for adhesions commonly encountered during other laparoscopic procedures.
PMID: 16555020 [PubMed - as supplied by publisher]
Copyright Status
Government information available from this site is within the public domain. Public domain information on the National Library of Medicine (NLM) Web pages
may be freely distributed and copied. However, it is requested that in any subsequent use of this work, NLM be given appropriate acknowledgment.



Find out about ARD before you have any surgery!